Taysha (NASDAQ: TSHA) insider plans 1,655-share Rule 144 stock sale

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. insider Kamran Alam has filed a Rule 144 notice to sell 1,655 shares of common stock through broker Maxim Group LLC on or about 02/04/2026, with an aggregate market value of 7,811.6. The company had 273,919,373 common shares outstanding.

The 1,655 shares to be sold were acquired on 02/03/2026 via an RSU award from the issuer, vesting and settling in stock as compensation for continued employment. In the past three months, Alam previously sold 78,968 and 23,849 common shares for gross proceeds of 375,098.00 and 109,943.89, respectively.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 06:38 PM Learn about SEC filing dates

FAQ

What does the TSHA Form 144 filing by Kamran Alam disclose?

The Form 144 shows that insider Kamran Alam plans to sell 1,655 shares of Taysha Gene Therapies common stock under Rule 144. The sale will be executed through Maxim Group LLC on or about February 4, 2026, on the Nasdaq exchange.

How many TSHA shares is the insider currently planning to sell under Rule 144?

The notice states that 1,655 shares of Taysha Gene Therapies common stock are planned for sale. These shares have an aggregate market value of about 7,811.6 and will be sold on Nasdaq through Maxim Group LLC as broker.

How were the 1,655 TSHA shares being sold acquired by Kamran Alam?

The 1,655 shares were acquired on 02/03/2026 via an RSU award from Taysha Gene Therapies. The RSUs vested and were settled in stock, with consideration described as the reporting person’s continued service as an employee of the issuer.

What prior TSHA stock sales by Kamran Alam are reported in this Form 144?

The filing lists two recent sales of Taysha Gene Therapies common stock: 78,968 shares sold on 01/23/2026 for 375,098.00, and 23,849 shares sold on 01/26/2026 for 109,943.89, both by Kamran Alam at the issuer’s Dallas address.

How many Taysha Gene Therapies (TSHA) shares are outstanding in this filing?

The Form 144 notes that 273,919,373 shares of Taysha Gene Therapies common stock were outstanding. This figure provides context for the planned Rule 144 sale of 1,655 shares, showing the sale size relative to the total share count.

Which broker will handle the planned TSHA Rule 144 stock sale?

The planned sale of 1,655 Taysha Gene Therapies common shares will be handled by Maxim Group LLC. The broker’s address is listed as 300 Park Avenue, 16th Floor, New York, NY 10022, and the shares are to be sold on the Nasdaq exchange.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	1655	7811.6	273919373	02/04/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/03/2026	RSU Award	Issuer			1655	02/03/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kamran Alam c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/23/2026	78968	375098.00
Kamran Alam c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/26/2026	23849	109943.89

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)